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Abbreviations 
CagA cytotoxicity associated gene A 
CU chronic urticaria 
FcsRIa a-chain of the high-affinity IgE receptor 
hcpA H. pylori cystein-rich 28 kD protein 
HLA histocompatibility leucocyte antigen 
H. pylori Helicobacter pylori 
hsp heat shock protein 
Ig immunoglobulin 
lpp20 lipoprotein 20 
OMP outer membrane protein 
T4 thyroxine 
TG antithyroglobulin antibody 
TSH thyroid-stimulating hormone 
TPO antithyroid peroxidase 
VacA vacuolating cytotoxin A 
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Summary 
The role of Helicobacter pylori in the pathogenesis of chronic urticaria (CU) has been 
questioned until recently. It is tempting to speculate that it triggers urticaria by means of an 
immunoglobulin E (IgE)-mediated pathway. H. pylori-specific IgE and consecutive mast cell 
and eosinophil activation take part in a local inflammatory process due to infection and in H. 
pylori-associated gastritis and ulcer. I have demonstrated an elevated total serum IgE level as 
compared with that in seronegative CU patients (I). Nevertheless, H. pylori-specific IgE is 
not common in CU, and there might not be a link between H. pylori and CU. 
My findings have strengthened a beneficial effect of eradication therapy on the 
course of CU (I). After a follow-up of 12 weeks, there was a significant difference in the 
symptoms of previously seropositive, but eradicated and seronegative chronic idiopathic 
patients. The resolution of chronic inflammation in H. pylori gastritis is slow, and the 
healing takes several months. This explains the observation that the healing or improvement 
of CU occurred within 3-12 weeks after successful eradication. 
Thes data support the hypothesis that H. pylori could play an indirect role as a 
triggering factor in the pathogenesis of CU. 
H. pylori has several immunoreactive proteins, which take part in humoral and 
cellular immunoreactivity. Antigastric antibodies play a role in the pathogenesis of gastric 
mucosal atrophy and gastritis. Type A gastritis (corpus-restricted autoimmune gastritis) is 
often associated with pernicious anaemia, an autoimmune disease. Immunoreactivity against 
some H. pylori proteins, mainly structural proteins and products, leads to cross-reactivity 
between essential human and H. pylori proteins, which gives rise to extradigestive 
autoimmune diseases. 
Previous studies have demonstrated a relation between the results of autologous 
serum tests and H. pylori, which suggests its role in autoimmune urticaria. I have found a 
connection between autoimmune urticaria and the most frequent organ-specific autoimmune 
disorder, autoimmune thyroiditis. The association was modified by the presence of H. pylori 
(II). 
A further possible link might be a H. pylori-specific 20 kD lipoprotein. Lipoprotein 
may act as an autoimmune target protein in several autoimmune diseases (systemic lupus 
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erythematosus and rheumatoid arthitis). I have demonstrated a significant difference in 
immunoreactivity against lipoprotein20 between CU and non-CU patients (III). 
In conclusion, my findings support the hypothesis that H. pylori infection may be 
involved in the pathogenesis of CU. However, it may be not the primary cause of CU, but 
rather a triggering factor involved in several different pathways. Accordingly, the eradication 
of H. pylori infection is required in seropositive patients because this may have a beneficial 
role in the course of CU. 
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Introduction 
Chronic urticaria (CU) is one of the most frequent skin disorders. My survey of 
18,000 normal adults in Szolnok County permitted an estimate that approximately 0.28% of 
the Hungarian population have CU (Bakos 2002). A population study in Sweden indicated 
that 0.11% of the men and 0.14% of the women suffered from CU (Hellgren 1972). 
CU is not a single disease. There are a number of subsets that exhibit both clinical 
similarities and differences. Physical urticaria and urticaria vasculitis manifest striking 
differences as compared to "regular" urticaria in the clinical picture, histopathology and 
aetiology. Accordingly it is necessary to distinguish these subsets from CU. 
CU is a polyaetiological disease. A number of factors have been identified that 
appear to be important in the pathogenesis of CU, including immunologic, pseudo-allergic 
reactions, some internal diseases and infections. Most patients believe that they have food 
allergy. This can be confirmed as a cause of CU in only 1% of all cases. Food additives can 
be demonstrated to be causative in no more than 5% (Greaves 2000). Chronic infections and 
infestations, including "focal" bacterial infections, candidiasis, parasites and protozoa such 
as Enterobius vermicularis, Giardia lamblia, Shistosoma, and hepatitis B and C viruses are 
relative often (15%) attributed as possible initiating factors of CU (Henz et al. 1998, 
Trachsel et al 1999). 
In 1986, the presence of a serum factor was reported that caused whealing in 
response to autologous intradermal serum in some patients with CU (Grattan et al. 1986). In 
1993, an immunoglobulin G (IgG) autoantibody directed against the a-chain of the high-
affinity IgE receptor (FcsRIa) was identified (Hide et al 1993). This causes whealing upon 
autologous injection into the patient's skin and releases histamine from human mast cells 
and basophils («Sabroe et al. 1998). Subsequent studies have indicated that 25-45% of 
patients with CU have anti- FcsRIa and 5% anti-IgE antibodies ([Fiebiger et al. 1995, Niimi 
et al. 1996). The anti-FcsRIa antibodies belong predominantly to the complement-fixing 
subtypes IgGl and IgG3 (Fiebiger et al. 1998). IgG anti-FcsRIa antibodies cause direct 
cross-linking of adjacent receptors, thus triggering mast cell or basophil activation (Greaves 
2000). This process requires complement activation, and C5a anaphylatoxin in particular 
(Fiebiger et al. 1998, Ferrer et al. 1999). Only CU patients have been shown to manifest 
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functional histamine-releasing anti-FcsRIa autoantibodies. Immunoreactive non-histamine-
releasing FceRIa autoantibodies have been found in autoimmune connective tissue diseases, 
autoimmune bullous diseases and in physical urticaria, and in other skin disorders such as 
atopic eczema (Fiebiger et al. 1998, Greaves 2000), but they have beenfound to be mainly 
of the IgG2 or IgG4 subtypes (Fiebiger et al. 1998). 
The skin-restricted distribution of the symptoms of CU could be explained by the fact 
that this activation occurs only in dermal mast cells, and not in other organs and tissues. The 
reason is not exactly clear. In vitro, lung and other non-cutaneous mast cells release 
histamine in response to anti-FceRIa autoantibodies (Niimi et al. 1996). Lung mast cells are 
unresponsive to activated complement. Mast cells of the skin, but not of the lung or intestinal 
mucosa, express C5aR (Fureder et al. 1995). 
Patients with autoantibodies (anti-FceRIa or anti-IgE) compose a subset of CU, 
autoimmune urticaria, but they have no distinctive clinical features. They exhibit 
exceptionally low peripheral basophil numbers and reduced basophil histamine releasibility 
(Sabroe et al. 1999a). Histologic examination reveals pronounced eosinophil degranulation 
(Sabroe etal. 1999b.). 
The diagnosis of autoimmune urticaria is based on autologous serum skin tests. A 
positive test is suggestive, but not diagnostic; confirmation is needed by the in vitro testing 
of autoantibodies by ELISA, Western blotting or basophil histamine release (Greaves 2000). 
A dilution of 1:10 and 1:100 of autologous sera for screening has been suggested to separate 
aspecific positivity (Husz 2002). 
The clinical course of autoimmune urticaria does not differ markedly from that of 
non-autoimmune urticaria, but the patients have more severe urticaria, which tends to be 
prolonged and less responsive to antihistamine therapy (Greaves 2002). 
There is also evidence of an association of autoimmune diseases in some patients 
with CU. Our results revealed specific and non-specific markers of polysystemic 
autoimmune diseases in CU. The most common finding was a non-specific marker of 
rheumatoid factor (9.5%) (JBakos et al. 1995). Similar results have been reported (Ryhal et 
al. 2001). 
The prevalence of thyroid autoimmunity in CU is as high as 14-20% (Leznoff et al. 
1983, Ryhal et al. 2001) and there is also an increased prevalence of CU in autoimmune 
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thyroid disease (Lanigan et al. 1987). The association of non-endocrine organ-specific 
autoimmune diseases with autoimmune thyroiditis is well known as autoimmune 
polyglandular syndrome. 
A positive autologous serum skin test was previously described in patients with 
urticaria associated with thyroid autoimmunity (Gaig et al. 2000). This suggests a 
correlation of chronic autoimmune urticaria and autoimmune thyroiditis in the same way as 
other organ-specific autoimmune diseases. The pathomechanism of the connection between 
thyroidal autoimmunity and CU, and especially autoimmune urticaria, is not clear. One 
possible explanation is the influence of a non-specific inflammatory mechanism (Leznoff and 
Sussman 1989) or the thyroidal effects in many cytokines (Turktas et al. 1997). Leznoff and 
Sussman suggested that patients with CU continuously produce excess quantities of 
cytokines and this is related to the development of autoimmune thyroiditis. Against this 
hypothesis is the fact that autoimmune thyroiditis may precede CU by several years, whereas 
other patients have a remission in CU with continuation of the thyroid disease. Further 
speculation is a cross-linking of the IgE receptors of mastocytes induced by antithyroid 
antibodies (Delevaux et al. 2001). 
Recent investigations have demonstrated a strong association of autoimmune 
urticaria with histocompatibility leucocyte antigen (HLA) DRB1*04 (DR4) and its 
associated allele, DQB 1*0302 (DQ8) (O'Donnell et al. 1999). Several studies have been 
preformed regarding the genetic suspectibility to autoimmune thyroid disease and have 
determined a strong association of Graves' disease with HLA haplotype DRB1*03 (DR3) in 
a Caucasian population (Hunt et al. 2001). On the other hand, patients with multiple 
autoimmune diseases, i.e. Graves'disease, type 1 diabetes mellitus and Hashimoto 
thyroiditis, shared the HLA haplotypic variant of DR4-DQ Al*0301 and DQB 1*0302 
(Einarsdottir et al. 2003). I hypothesize that genetic susceptibility to autoimmunity might 
predispose to associated autoimmune disorders such as autoimmune urticaria and 
autoimmune thyroiditis. The susceptible HLA loci could be responsible for the coexistence 
of the two diseases. 
In the past decade, there have been many conflicting studies concerning CU and its 
association with Helicobacter pylori infection. 
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H. pylori is one of the most frequent human bacteria; more than half the world's 
population harbour H. pylori. It is generally accepted that H. pylori infection plays an 
aetiologic role in the development of chronic active gastritis, peptic ulcer disease, gastric 
adenocarcinoma and low-grade gastric mucosa-associated lymphoid tissue lymphoma. 
Recently, a potential role of H. pylori infection in several extraintestinal pathologies has 
been suggested (Realdi et al. 1999). 
H. pylori affects a high proportion of patients with CU, but the seroprevalence does 
not differ from that for the normal population. Bacterium eradication is associated with a 
remission of the CU symptoms, suggesting its possible role in the pathogenesis of CU 
(Rebora et al. 1995, Di Campli et al. 1998, Wedi et al. 1998, Wustlich et al. 1999), but 
contradictory results have also been published (Becker et al. 1998, Valsecchi et al. 1998, 
Schnyder et al. 1999). 
Previously, the main attention focussed on the humoral immunoreactivity against H. 
pylori. Both local and circulating antibodies can be demonstrated in infected patients. Serum 
anti-H. pylori IgG antibody titres are significantly correlated with the severity of 
inflammation. The decreased IgG, IgM and IgA antibody titres after eradication are of 
diagnostic value. The screening of serum IgG and IgA antibodies is widely used in the 
diagnosis of the infection. Hungarian authors first described an increased level of IgE-
producing plasma cells in H. pylori-infected gastric mucosa (Berczi et al. 2000). Elevated 
total IgE levels have been observed in H. pylori-associated gastritis and ulcer and specific 
anti-H. pylori antibodies bound to basophil leukocytes have been identified in the sera of 
seropositive patients (Aceti et al. 1991). Specific IgE takes part in local inflammation via the 
degranulation of mast cells caused by subsequent antigen stimuli. Patients infected with H. 
pylori show elevated levels of eosinophil cationic protein, eosinophil cationic factor and 
major basic factor, which is a consequence of local eosinophilia {Berczi et al. 2000). 
Eosinophils could also serve as a direct target due to their low-affinity IgE receptors. IgE 
and eosinophilia may represent a normal inflammatory reaction in part of the late-phase type 
I immune response against H. pylori (Fekete 1998). Nevertheless, H. pylori-specific IgE is 
not common in CU (Liutu et al. 1998), and there might not be a link between H. pylori and 
CU. However, a modulatory action of H. pylori on histamine release from mast cells and 
basophils has been established (.button et al. 1995). 
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Despite early immune responses, H. pylori infection is associated mainly with the 
Thl response that is responsible for the epithelial damage and gastroduodenal morphologic 
alterations. Hungarian authors recently demonstrated enhanced lymphocyte reactivity to H. 
pylori in CU (Hídvégi et al. 2001). In CU, there could be an increased cellular reactivity as a 
consequence of underlying continuous autoantigen stimulation (e.g. FceRIa or antithyroid 
peroxidase [TPO]), which would be enhanced by H. pylori-induced lymphocyte 
responsiveness. 
Complement activation takes part in host reactivity against H. pylori. In the absence 
of complement, marked amounts of bacteria remain extracellularly attached. If complement 
is present, internalization and morphological destruction are significantly enhanced. Coating 
the bacteria with IgG and IgM results in complement activation liberating C5a (Mollenkopf 
et al 1990). H. pylori and its lipopolysaccharides engage in the classical activation pathway. 
Complement activaton and consecutive consumption by antibodies directed against H. pylori 
are so excessive that they result in acute episodes of hereditary angioneurotic oedema 
(Farkas et al. 2001). Complement activation and circulating anaphylatoxins (C5a and C3a) 
have an enhancing effect on mast-cell degranulation. "Focal" infection can activate 
complement, leading to the allergic reactions frequently seen in everyday dermatological 
practice and in the pathogenesis of urticaria (Bakos et al. 1990; 1995). By liberating C5a 
anaphylatoxins, H. pylori infection might costimulate effects of FceRIa on skin mast cells, 
and could henceplay a trigger role in autoimmune urticaria. 
H. pylori colonizes the gastric mucosa and leads to gastric mucosal damage. It can 
alter the structure and the mucus composition, and a decrease of the epithelial barrier 
integrity could lead to an increased absorption. This increased permeability to antigens could 
be responsible for allergic sensitization to food antigens. Specific IgE against food antigens 
has been demonstrated in connection with H. pylori in patients with ulcer (DeLazzari 1989). 
A number of studies have reported an association of H. pylori infection with food allergy 
(Corrado et al. 1998, Figura et al. 1999). We confirmed a correlation between the presence 
of food-specific IgE and H. pylori infection in CU in one study (Bakos 2002). 
A sensitization to food antigens due to H. pylori-cmsed enhanced absorption has also 
been implicated in the pathogenesis of CU. 
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The resolution of chronic inflammation in H. pylori gastritis has been demonstrated 
to be a slow process, the healing requiring several months (Valle et al. 1991). This finding 
explains the observation that the healing or improvement of CU occurred within 3-12 weeks 
after successful eradication treatment (see in Chapter 1). 
Despite conflicting results of eradication therapy, H. pylori may have an indirect role 
in urticaria (Greaves 2001). The positive correlation between a positive autologous test and 
H. pylori (Hizal et al. 2000) suggests its role in the autoimmune pathogenesis of urticaria. 
I found a characteristic difference in prevalence of H. pylori in autoimmune urticaria with 
coexistent autoimmune thyroiditis as compared with that without thyroid autoimmunity (see 
in Chapter 2). 
The evidence suggests that bacterial proteins could elicit autoimmunity as a 
consequence of molecular similarity to human antigens. H. pylori may play a part in 
triggering autoimmunity, possibly as a result of the high degree of sequence homology 
exhibited by the heat shock protein 60 (hsp60) family (Barton et al. 1998), although other 
factors such as cross-reactivity between Lewis X and Y antigens and bacterial 
lipopolysaccharide may also be important (Aspinall et al. 1996). Autoantibodies against 
hsp60 perpetuate mucosal permeability via damage to the gastric epithelial cells (Barton et 
al. 1998). 
Lipoprotein 20 (lpp20) is an outer membrane protein. The outer membrane is a 
continuous structure on the surface of Gram-negative bacteria. H. pylori may shed part of its 
outer membrane as vesicles when the cells are growing. They could then be released into the 
extracellular space and enter the gastric mucosa. The extracellular release of soluble H. 
pylori proteins may have important functional consequences, including a potential role in 
inciting a gastric mucosal inflammatory response (Mai et al. 1991). They are of particular 
significance as a potential target for protective immunity (Keenan et al. 2000b). The 19 kD 
band represents lpp20, which has a classical lipoprotein signal sequence (Kostrzynska et al. 
1994). Lipoproteins have a structural similarity to oxidized low-density lipoprotein, so they 
could elicit autoimmune reactivity (Vaarala et al. 1993). 
We previously found that the prevalence of anti-H. py/on-associated lpp20 antibody, 
analysed by Western blot, was considerably higher in H. pylori-positive patients with CU 
than in H. /jy/on'-positive patients without it (Bakos et al. 2000). In order to assess the 
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occurrence of H. pylori infection in CU, we extended our preliminary observation of the 
high prevalence of anti-lpp20 antibodies in H. pylori-positive patients with CU. (see in 
Chapter 3) 
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Chapter 1 
Effects of Helicobacter pylori eradication on chronic urticaria 
1.1. Patients and methods 
A total of 36 chronic idiopathic urticaria patients were enrolled in this study. The 
patients were examined at the Department of Dermatology, Hetenyi Hospital, Szolnok 
during 1996-97. They were investigated according to a previous study (Bakos et al. 1995). 
Patients with urticarial vasculitis, hereditary angioedema and physical urticaria were 
excluded from the study. 
Routine diagnostic approach 
The patients underwent a full investigation of the history, physical examination, 
consultation with the gynaecologist, urologist, dentist and ENT specialist, dental and sinus 
radiography, abdominal ultrasonography and laboratory tests: eythrocyte sedimentation rate, 
complete blood counts, urinanalysis, liver and kidney functions, hepatitis serology, 
antinuclear antibody (Hep2 cell, indirect immunofluorescence), anti-SSa, anti-SSb, 
complement activation and stool examination. Intradermal testing was performed with a 
mixture of grasses, tree pollens, ragweed, cereals, mugwort, housedust mite, cat hair, dog 
hair, cow milk, egg, peanut, nuts and wheat (Allergopharma). Epicutan tests (European 
standard, Epipharm) were performed. Total IgE was investigated by IgE Quick. 
Determination of H. pylori infection 
All patients were subjected to oesophagogastroduodenoscopy, and biopsies were 
taken from the gastric antrum and corpus. The presence of H. pylori was asessed by Giemsa 
staining and by a rapid urease test. H. pylori-specific IgG determination was performed by 
RIDA®(R-Biopharm GmBH, Darmstadt, Germany). 
Treatment and follow-up of H. pylori infection 
Patients who were infected with H. pylori were given triple antimicrobial treatment 
consisting of omeprazole 2x20 mg daily in the first week (lx 20 mg daily in the second 
week), 2x500 mg clarithromycin daily and 2x1000 mg amoxycillin daily for 2 weeks. 
During the eradication, concomitant treatment with the non-sedating antihistamins loratadine 
(10 mg daily) was allowed for patients with CU symptoms. 
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Four weeks after the completion of therapy, the effectiveness of eradication was 
assessed by gastroscopy, urease tests and serum tests for circulating H. pylori antibodies. 
The effect of the treatment on urticaria was evaluated via a symptom score system (0-3 
score) during 12 weeks. 
Statistical methods 
Fisher's exact test was applied to compare the prevalence of H. pylori infection in the 
study groups and the normal population. Analysis of variance between the values of IgE was 
estimated with the Mann-Whitney test. A probability level p < 0.05 was considered 
statistically significant. 
1.2. Results 
Examinations were performed on 36 patients with CU: 24 women and 12 men aged 
between 20 and 74 years (mean 41.3 ± 16.4). None of them had CU of known etiology, e.g. 
foci, food allergy, intolerance reaction or contact allergy with the exception of possible 
infection with H. pylori. Gastroscopy did not reveal any morphologic changes in the 
patients. The urease test was positive in 25 of the 36 (69%). 11 of the 36 patients remained 
idiopathic after investigation for H. pylori. H. pylori infection was detected in biopsy 
specimens of these patients. Urease testing and direct staining of biopsy specimens indicated 
that the "negative" patients did not have morphologic disturbances or H. pylori colonization. 
H. py/ori-associated gastritis was diagnosed by histopathologic examination in the patients 
infected by the bacterium, although it was mild. 
There was a higher prevalence of H. pylori seropositivity in younger (aged 20-34) 
and middle-aged (aged 45-55) patients with CU as compared with previously published 
results from a representative sample of the Hungarian population (Tamassy et al. 1995), 
whereas the age distribution of the studied individuals did not differ significantly (Figure 
I.1). 
The serum total IgE was elevated in 19 of the 25 H. pylori-infected patients, but in 
none of the H. pylori-negative patients (176.4 kU/L vs. 46 kU/L) (p<0.03). 
All the H. pylori-infected patients received eradication therapy. Control gastroscopy 
performed after 4 weeks revealed the presence of the bacterium in only 1 case; a second 
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course of treatment proved necessary. Successful eradication was confirmed by histology 
and by urease testing in 24 patients. H. pylori-specific IgG was positive in all 24 patients. 
In 6 patients the CU was eliminated 2 weeks after eradication (follow-up 4 weeks), 
while in 8 patients it was improved significantly. Six weeks after eradication (follow-up 8 
weeks) complete remission was observed in 11 patients, and partial remission in 6, whereas 
at the end of the follow-up (12 weeks) there were 18 cases of complete (72%), and 4 of 
partial remission (16%). Eradication was not beneficial for the CU in 3 patients (12%). 
Taken together, a large majority (88%) of the patients who underwent H. pylori eradication 
therapy exhibited the disappearance or improvement of the CU (Figure 1.2). In contrast, 
among the seronegative patients with CU (n=ll), only 3 (27.2%) showed a significant 
improvement (a significant reduction of the CU symptoms and/or the use of antihistamines) 
and 2 (18.1%) a spontaneous remission within 12 weeks. 
1.3. Discussion 
H. pylori infection is one of the most frequent human infections. In this study we 
found a similar prevalence in CU relative to the normal population. There was a significant 
difference in the course of the symptoms in seropositive CU patients after eradication 
therapy as compared with seronegative patients with CU. In 88% of the seropositive patients, 
the CU symptoms disappeared or improved after the eradication treatment, whereas the 
condition improved spontaneously in only 45.3% of the seronegative subjects. This is similar 
to the situation for untreated H. pylori seropositive patients (50%) (Wedi et al. 1998), which 
provides evidence for a causal relation between H. pylori gastritis and CU. 
The total IgE level was significantly higher in the seropositive patients than in the 
seronegative group. Other authors have shown that one-fifth of the patients present elevated 
total IgE serum levels (DeLazzari et al. 1994). 
During viral or bacterial infections of the digestive tract, the intestinal permeability to 
food antigens generally increases, because of the alterations caused in the gastrointestinal 
epithelium by infectious agents and by the inflammatory reaction. In the context of such an 
inflammatory environment, the local antigen-presenting cells (mainly dendritic cells) switch 
from a tolerogenic to an immunogenic state. This process favours the development of an 
immune response instead of the normal suppressive response, which is the basis of oral 
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tolerance. The bacterial and viral stimuli could also modify the intestinal permeability to 
food antigens due to the alteredbarrier function of the epithelium, or could activate the 
costimulatory molecules at the surface of local antigen-presenting cells. However, the 
increased intestinal transport of macromolecules does not lead systematically to an increased 
allergic sensitization. Not only a genetic susceptibility plays a role in the development of 
allergic responses to food antigens absorbed in the intestine, but also other factors that 
interfere with antigen presentation, such as the type of antigen, the type and status of the 
antigen-presenting cell, the presence of bacterial adjuvants, the expression of costimulatory 
molecules at the time of presentation, or the cytokines present during T-cell activation. 
The bacterial intestinal microflora plays an important role in the immune responses to 
luminal antigens. Nonpathogenic bacteria (probiotics) have recently been shown to attenuate 
the synthesis of proinflammatory effector molecules (NFkB) elicited by diverse 
proinflammatory stimuli, including pathogenic bacteria (Neish et al. 2000). The mechanism 
of such an inhibitory effect consists in the blockade of inhibitory k(3-(x degradation, 
preventing subsequent nuclear translocation of the active NFkB dimer and then the 
transcription of genes coding for inflammatory cytokines. 
H. pylori colonization induces a strong inflammatory response in the gastroduodenal 
mucosa, with a consecutive enhanced permeability of the gastric mucosa. The gastric 
epithelium, like the small intestine epithelium, is able to absorb small amounts of 
macromolecules, and this antigen absorption may induce the IgE-mediated sensitivity 
reactions to these antigens (Matysiak-Budnik et Heyman 2002). The stomach is considered a 
major site of involvement in food-induced hypersensitivity reactions. A marked increase in 
the number of IgE-producing cells in the gastric mucosa has been observed in patients with 
peptic ulcers infected by H. pylori (Berczi et al. 2000). Significantly higher total IgE serum 
levels were found in patients with peptic ulcers than in healthy subjects {De Lazzari et al. 
1994) 
It has recently been reported that inflammation and enhanced permeability in H. 
pylori gastritis directly stimulates IgE production in response to the most common 
alimentary allergens, even in patients without clinical evidence of allergy (Figura et al. 
1999). Specific IgE induced by food and inhalant allergens has been found in 28% of peptic 
ulcer patients and 4% of controls (De Lazzari et al. 1989). 
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A number of data support the possible association between H. pylori and food 
allergy. Bacteria can colonize the gastric mucosa and alter the gastric barrier. All the 
bacterial factors, and also the inflammatory mediators, may lead to gastric mucosal damage. 
Increased gastric permeability to sucrose has been found in patients infected with H. pylori 
{Fucuda et al. 2001). The experimental data indicate that H. pylori can increase the passage 
of intact antigens across the epithelial barrier (Matysiak-Budnik et Heyman 2002). 
It has been demonstrated that there is a higher percentage of infection with this 
pathogen among food-allergic children than among the control group (Corrado et al. 1998). 
We have observed a relationship between sensitization to food and H. pylori. The prevalence 
of food-specific IgE was 41.4% in CU patients with vs. 7.1% in patients without H. pylori 
infection (Bakos et Szemere 2002). 
Previous data indicated that healing or improvement occurred within 3-12 weeks 
after eradication therapy (Table 1.1). 
The absorption of vasoactive ingredients and the passage of food components 
through the barrier continue long after eradication because the polymorphonuclear 
infiltration and epithelial damage diminish only after some period. On the other hand, food 
allergy increases the intensity of gastric inflammation, which leads to the persistence of 
gastric inflammation for months and even years after eradication of the bacterium. 
These data strengthen the hypothesis that in some subjects, chronic infection with H. 
pylori may play a role in the development of allergic sensitization to food antigens. 
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Figure 1.1. Comparison of data obtained from a representative sample of the 
Hungarian population (Tamdssy et al. 1995) with present data on CU patients (n=36) 
120 
SS 20 
20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 
Age groups 
Figure 1.2. Course of CU after eradication therapy 
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Table 1.1. Studies relating to the frequency of H. pylori infection in CU and the 
effectiveness of eradication therapy 
Reference H.pylori- Eradicated Follow-up Course of CU 
positive period after eradication 
cases (weeks) 
Kolas et al.(1996) 17/40 17 8-12 Significant improvement 
Tebbe et al. (1996) 14/25 14 8-10 6 PR, 8 CR 
Bohmeyer et al. (1996) 8/10 8 4 CR 
Wedi et al (1998) 47/100 21 12 14 CR, 5 PR 
Bakosetal. (1998) 25/36 25 12 4 PR, 18 CR 
PR: partial remission, CR: complete remission, CU chronic urticaria 
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Chapter 2. 
Comparison of chronic autoimmune urticaria with chronic idiopathic urticaria 
(effects of Helicobacter pylori on pathogenesis of autoimmune urticaria) 
2.1. Patients and methods 
Patients 
Forty-eight patients (30 women and 18 men, aged 14 to 75 years; mean: 40.8 ± 16.4 
years) with CU were investigated. They had no food allergy or intolerance, contact allergy, 
bacterial focus or parasitic infection, physical urticaria, urticarial vasculitis, 
hypocomplementaemic urticaria or polysystemic autoimmune diseases. The duration of the 
symptoms ranged between 2 and 240 months (mean 18.4 ±19.1). 
Autologous serum test 
0.1 mL of autologous serum and autologous serum diluted 1:1 with physiological 
saline were administered to the patients' forearms (flexor sides). The reaction was examined 
30 minutes later. A wheal with a diameter at least 1.5 mm greater than that of a control 
wheal induced with saline solution was accepted as positive {Greaves 2000). 
Thyroid function and autoantibodies 
Thyroxine (free T4) and thyroid-stimulating hormone (TSH), antithyroid peroxidase 
antibody (TPO) and antithyroglobulin antibody (TG) levels were investigated. Free T4 and 
TSH were measured by Microparticle Enzyme Immunoassay (MEIA) (Abbott Laboratories, 
USA), and TG and TPO by sequential immunometric assay with an IMMULITE Analyser 
(DPC, United Kingdom). 
Determination of H. pylori infection 
All patients underwent gastroscopy and urease testing. They had no dyspeptic 
symptoms in their history or during the observation period and only mild gastritis was seen 
on endoscopy. H. pylori-specific IgG determination and immunoblotting for the detection of 
antibodies (IgG) against H. pylori were performed by RIDA® (R-Biopharm GmBH, 
Darmstadt, Germany) with the following molecular weights: 120 kD cytotoxicity associated 
gene A (CagA), 87 kD (VacA), 67 kD (OMP 67), 62 kD (urease B), 58 kD (hsp), 54 kD 
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(flagellin), 47 kD, 33 kD, 29 kD (urease H), 28 kD (hcpA - H. pylori cysteine-rich protein 
A), 25 kD (urease D) and 19 kD. 
Statistical methods 
Fisher's exact test was applied to compare the prevalence of thyroid autoimmunity 
and H. pylori infection in the two study groups. Analysis of variance between the values of 
basophil cells and IgE was performed with the Mann-Whitney test. A probability level p < 
0.05 was considered statistically significant. 
2.2. Results 
The 48 patients with CU were divided into two subgroups on the basis of the results 
of autologous serum tests. The autologous serum test was positive in 26 patients (54.2%): 16 
women and 10 men (autoimmune group). The autologous serum test was negative in 22 
patients (45.8%): 13 women and 9 men (non-autoimmune group). 
The basophil cell count was 0.030 ±0.012 109/L in the autoimmune group, and 0.046 
±0.011 109/L in the non-autoimmune group; the difference was significant: p = 0.001. The 
IgE level was 175.7 ± 196.7 IU/mL in the autoimmune group, and 213.2 ± 237.9 IU/mL in 
the non-autoimmune group, but the difference was not significant {Table 2.1). We found no 
difference in the prevalence of H. pylori infection between the two groups. On the basis of 
the urease test, the histology and the H. pylori-specific IgG, 17 of the 26 autoimmune cases 
(65.4%) and 13 of the 22 non-autoimmune cases (59.1%) were infected with H. pylori. 
The prevalence of antithyroid antibodies was different in the two groups of CU 
patients. In the autoimmune group, we found 11 patients (42.3%) with TPO, whereas in the 
non-autoimmune group, there were 3 patients (13.6%) with TPO. The difference in 
prevalence of TPO between the two groups was significant (p = 0.03). None of the patients 
had known of the thyroid disease previously. The prevalence of TG did not differ 
significantly in two groups (4 vs. 1 patients; 18.2% vs. 3.8%). Two patients from the 
autoimmune group with an elevated TPO had a lowserum TSH level; accordingly, the 
condition was considered to be subclinical hyperthyroidism. Both patients were examined by 
an endocrinologist. 
In a further analysis of the autoimmune patients with TPO, we found differences in 
frequency of H. pylori infection as compared with the autoimmune patients without TPO 
{Table 2.2). We found 10 patients with TPO infected with H. pylori (90.9%) in the 
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autoimmune group, only 1 patient in this group being non-infected. Of the 15 autoimmune 
patients without TPO, 7 (46.7%) were infected with H. pylori. The difference in the 
prevalence of H. pylori infection was significant between autoimmune urticaria with and 
without thyroid autoimmunity (p=0.02). 
We investigated H. pylori-specific IgG in all 17 infected patients in the autoimmune 
group (with and without TPO). We found antibody to 120 kD in 14 patients (82.4%), to 87 
kD in 16 (94.1%), to 67 kD in 16 (94.1%), to 62 kD in 6 (35.3%), to 58 kD in 17 (100%), to 
54 kD in 14 (82.4%), to 47 kD in 8 (47.1%), to 44 kD in 10 (58.8%), to 33 kD in 9 (52.9%), 
to 29 kD in 12 (70.6%), to 28 kD in 16 (94.1%), to 25 kD in 13 (76.5%), and to 19 kD in 16 
(94.1%). The H. pylori-specific IgG antibodies revealed a similar prevalence in the subjects 
with TPO (10 patients) and in those without TPO (7 patients), except for 120 kD CagA: 
(patients with vs. without TPO: 120 kD: 10 vs. 4; 87 kD 9 vs. 7; 67 kD: 10 vs. 6; 62 kD: 4 vs. 
2; 58 kD: 10 vs. 7; 54 kD: 8 vs. 6; 47 kD: 5 vs. 3; 44 kD: 5 vs. 4; 33 kD: 5 vs. 4; 29 kD: 7 vs. 
5; 28 kD: 9 vs. 7; 25 kD: 8 vs. 5 and 19 kD: 9 vs. 7.) The difference between the patients 
with and without thyroid autoimmunity was significant only in the case of 120 kD 
(p < 0.05). 
2.3. Discussion 
The clinical diagnosis of autoimmune urticaria is currently based on autologous serum 
skin testing. We distinguish two groups of CU patients on the basis of the result of the 
autologous skin test. We found no laboratory differences between the autoimmune and 
non-autoimmune groups except for the basophil count, in accordance with the previous data 
{Greaves 2000). 
We observed a relationship between autoimmune urticaria and autoimmune thyroiditis. 
A positive autologous serum skin test was previously described in patients with autoimmune 
urticaria associated with thyroid autoimmunity {Gaig et al. 2000). 
We found a high prevalence of thyroid autoimmunity among the CU patients, though 
all but 2 cases of subclinical hypothyroidism would have remained unrecognized without 
investigation of the thyroid autoantibodies. Despite the high titres of thyroid autoantibodies, 
most patients remain asymptomatic for years and have a normal thyroid function; ultimately, 
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however, a substantial proportion of these patients develop overt hypothyroidism (Leznoff et 
al. 1983). Our results suggest that a complete thyroid examination with hormone and 
autoantibody assays should be performed, because examination of the thyroid function alone 
is insufficient in CU. 
In the present study, we found a characteristic difference in theprevalence of H. 
pylori in autoimmune urticaria with coexistent autoimmune thyroiditis as compared with that 
without thyroid autoimmunity. A high seroprevalence of H. pylori infection was earlier 
observed in patients with autoimmune thyroiditis (Figura et al. 1999). 
There is growing evidence that the phenomenon of parasite-host mimicry may initiate 
or maintain autoimmunity. Abundant data point to the presence of cellular and humoral 
autoimmune responses in patients with H. pylori infection (Realdi et al. 1999). In a 
mechanism known as antigen mimicry, highly conserved immunologic molecules expressed 
by infectious pathogens may act as a trigger for the immune responses that cross-react with 
the host cellular antigens. A great number of cross-reacting antibodies take part in the 
pathogenesis of the stomach and duodenal alterations caused by H. pylori, e.g. antibodies 
against H. pylori cross-react with antral mucosal cells (the membrane of the secretory 
canalicular structures of the parietal cells) and gastrin-producing cells. Antigastric antibodies 
play a role in the pathogenesis of gastric mucosal atrophy and gastritis (Negrini et al. 1997). 
Type A gastritis (corpus-restricted autoimmune gastritis) is often associated with pernicious 
anaemia, an autoimmune disease. 
Various findings have previously been published suggesting an association between 
H. pylori infection and some extradigestive autoimmune ailments, such as Sjogren's 
syndrome (Figura et al. 1994), scleroderma (Kalabay et al. 2002), Henoch-Schonlein 
purpura (Reinauer et al. 1995) and thyroiditis (Figura et al. 1999). The basic mechanism 
might be antigen mimicry between H. pylori antigens and several essential human antigens, 
as other infective agents can introduce or participate in an autoimmune pathogenesis. 
We found a connection between autoimmune thyroiditis and CagA + H. pylori 
strains. Monoclonal antibodies to a H. pylori strain with CagA positivity reacted with 
follicular cells of the thyroid gland, and the H. pylori organism possessing the CagA 
pathogenicity island carries a gene encoding for an endogenous peroxidase. There is a 
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molecular similarity between human thyroid peroxidase and H. pylori peroxidase; this 
causes immunologic cross-reactivity and might be a possible factor in the development of 
autoimmune thyroid disease (Figura et al. 1999). 
A positive correlation has been described between H. pylori infection and the result 
of the autologous serum skin test {Hizal et al. 2000). 
Our findings suggest the possibility of the triggering of cross-reactivity between CagA+ H. 
pylori strains and two connected autoimmune disorders, autoimmune thyroiditis and 
autoimmune urticaria. This indicates an indirect aetiological role of H. pylori in triggering 
autoimmune urticaria in at least a selected group of patients. 
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Table 2.1. Characteristics of patients with chronic autoimmune urticaria and chronic 
non-autoimmune urticaria 
Characteristics Autoimmune Non-autoimmune P 
(n= 26) (n= 22) 
Age 46.f >±18.6 36.1 ±18.9 0.03# 
Basophil cell count (G/L) 0.030 ±0.012 0.046 ±0.011 0.001# 
Total IgE (IU/mL) 175 .7 ±196.7 213.2 ±237.9 NS 
Infected with H. pylori (n / %) 17 (65.4%) 13 (59.1%) NS 
T P O A b ( n / % ) 11 (42.3%) 3 (13.6%) 0.03* 
TG A b ( n / % ) 4 (18.2%) 1 (3.8%) NS 
# Mann-Whitney test 
* Fisher's exact test 
Table 2.2. Survey of thyroid autoimmunity in patients with chronic autoimmune 
urticaria (n = 26) 
Characteristics With TPO Without TPO 
(n=ll) (n=15) 
Infected with H. pylori 10 (90.9%) 7 (46.7%) 
Without H. pylori 1 (9.1%) 8 (53.3%) 
Fisher's exact test: p=0.024 
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Chapter 3 
High prevalence of IgG and IgA antibodies to 19 kD Helicobacter pylori-associated 
lipoprotein in chronic urticaria 
3.1. Patients and methods 
Fifty-six patients (34 women and 22 men, 14 to 75 years of age; mean ± S.D.: 40.8 ± 
16.4 years) with CU were investigated. The duration of the disease varied between 2 and 240 
months (median: 6 months, IQ range: 3.5-18.0). They had no other underlying causes of 
urticaria, such as food allergy or intolerance, contact allergy, bacterial focus or parasitic 
infection, physical urticaria, urticarial vasculitis, hypocomplementemic urticaria or 
polysystemic autoimmune diseases. They had no dyspeptic symptoms in their history or 
during the observation period. 
The control group comprised a selected group of 33 H. pylori-positive, severely 
dyspeptic, but non-urticarial patients (12 men and 21 women, 24 to 75 years of age, mean: 
51.1 ± 13.3 years) with high grade histologically proven H. pylori-associated gastritis. All 
patients underwent gastroscopy, histology of the gastric mucosa and urease testing. The 
degree of gastritis was estimated by means of the Updated Sydney System. 
Anti-77. pylori-specific IgG and IgA were determined by the RIDA® test (R-
Biopharm GmbH, Darmstadt, Germany). Titres of >10 IU/L were considered positive, 
according to the values given by the manufacturer. Immunoblotting was performed with the 
RIDA® test (R-Biopharm GmbH, Darmstadt, Germany), with the following molecular 
weights: 120 kD (CagA), 87 kD (VacA), 67 kD (OMP 67), 62 kD (urease B), 58 kD (hsp), 
54 kD (flagellin), 47 kD, 33 kD, 29 kD (urease H), 28 kD (hcpA), 25 kD (urease D) and 19 
kD (lpp20). In the test are anti-human-IgG and IgA conjugates (IgG antibodies from rabbit 
conjugated with peroxidase). 
Fisher's exact test was applied to compare the anti-//. pylori antibody profiles and 
gastritis scores in the two study groups. Analysis of variance between the values of H. 
pylori-specific IgG and IgA was performed with the Mann-Whitney test. A probability level 
p < 0.05 was considered statistically significant. 
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3.2. Results 
H. pylori-specific IgG and IgA titres in patients with and without CU 
The 56 patients with CU were divided into two subgroups on the basis of the findings 
of gastroscopy and the urease test. Subgroup 1 comprised 33 urease-positive patients with 
mild gastritis on histology (score 1.3), while 23 urease-negative, non-gastritic patients 
formed subgroup 2 (Table 3.1). They were categorized as "idiopathic" urticarial patients. 
Whereas the H. pylori-specific IgG level was elevated (>10 IU/L) in each patient in 
subgroup 1, all the patients in subgroup 2 remained seronegative. In each patient in the 
control group, endoscopy and the histology demonstrated severe gastritis (score 3.8) and the 
H. pylori-specific IgG proved positive. The gastritis score was significantly higher in the 
control group than in subgroup 1 (Table 3.1). 
The H. pylori-specific IgA was positive in 13 of the 33 patients in subgroup 1. In 
subgroup 2, the anti-H pylori IgA levels were not elevated. In the control group, high anti-
H. pylori IgA levels were detected in 28 of the 33 patients (84.8%). The titres of anti-H 
pylori IgG and IgA antibodies were significantly higher in the control group than in 
subgroup 1 (p = 0.0128 and p<0.0001) (Table 3.1). 
Patients with and without CU exhibit different IgG and IgA profiles against H. pylori 
antigens 
Western blot analysis was performed on 33 H. pylori-positive patients with CU 
(subgroup 1) and in the control group. In subgroup 2, the low specific IgG or IgA 
(0-10 IU/L) did not furnish measurable values on Western blot analysis; accordingly, these 
patients were not included in the Western blot study. We observed a surprisingly higher 
prevalence of anti-lpp20 IgG antibodies (93.9%) in subgroup 1 than in the control group 
(21.2%, p < 0.0001) (Table 3.2). The IgG levels to other H. pylori antigens did not indicate 
any significant difference between these two groups (Fig. 3.1). 
Immunoblotting for IgA antibodies against H. pylori antigen determinants was 
performed in 13 H. pylori-positive patients with CU (all patients in subgroup 1 with elevated 
H. pylori-specific IgA) and in 16 control patients. There was a significant difference in the 
prevalence of anti-lpp20 IgA antibodies between the CU and the non-CU patients (46.1% vs. 
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6.3%, p = 0.0029) {Table 3.3). There were no significant differences between the two groups 
as regards the prevalence of other anti-H pylori IgA antibodies. 
3.3. Discussion 
We observed a characteristic difference in humoral immunoreactivity to H. pylori-
associated lpp20 between H. pylori-infected patients with CU, and H. pylori-positive 
patients without CU. As concerns the other H-pylori-associated antigen moieties, we found 
practically identical antibody patterns in the patients with and those without CU. 
The 19 kD band represents lpp20, a conserved H. pylori-associated lipoprotein that 
contains a classical lipoprotein signal sequence (Kostryzinska et al. 1994). Like many other 
Gram-negative bacteria, in some special conditions H. pylori may shed part of its highly 
antigenic outer membrane as vesicles, resulting in portions of the membrane blebbing off the 
surface of growing cells {Keenan et al. 2000b). They could then be released into the 
extracellular space and enter the gastric mucosa. This phenomenon may have important 
functional consequences, including a potential role in inciting a gastric mucosal response 
(Mai et al. 1991, Cao et al. 1998). Bacterial lipoproteins are not only targets of an immune 
response, but also act as immunostimulatory molecules {Haupl et al. 1997). They may play a 
role in the pathogenesis of several autoimmune diseases, e.g. rheumatoid arthritis and 
systemic lupus erythematosus (Vaarala et al. 1993). Furthermore, the 19 kD lpp20 may act 
as a protective antigen, but this protection depends on the magnitude and subclass of the 
response; for example, an IgGl subclass monoclonal antibody raised against H. pylori lpp20 
can reduce or even prevent H. pylori colonization {Keenan et al. 2000a). This protective 
antibody response may have a functional role in the prevention or mitigation of gastritis 
associated with H. pylori infection. 
Our CU patients had no dyspeptic symptoms in their history or during the 
observation period, and only mild gastritis was seen on endoscopy. This phenomenon may 
be explained by the protective effect of anti-lpp20 IgG antibody. On the other hand, people 
harbouring H. pylori with zero or low levels of anti-lpp20 may develop severe gastritis with 
overt dyspeptic symptoms, as observed in our selected dyspeptic control group. 
Our findings suggest that IgG and (in part) IgA antibodies to H. py/on-associated 
lpp20 (in addition to their putative gastroprotective effect) could act as a source of 
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autoimmunity, and may play a role in the pathogenesis of a subtype of CU, presumably via 
cross-reactivity between the bacterial lpp20 and some skin antigen components. Further 
investigation is needed to establish cross-reactivity between lpp20 and skin antigens. 
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Table 3.1. Titres of H. py/0/7-specific IgG and IgA in patients with and without CU 
Subgroup 1 
(CU with H. pylori 
infection) 
Subgroup 2 
(CU without H. 
pylori infection) 
Control group 
(H pylori-associated 
gastritis without CU) 
No. of patients 33 23 33 
Histologic score *p 1.3 0 3.8 
H. pt'/on-specific IgG 
No. of patients > 10 IU/L 33 (100%) 0 33 (100%) 
Median **p, +p 48.0 IU/L 3.6 IU/L 76.2 IU/L 
IQ range 23.8- 116.6 IU/L 0 - 5 . 9 IU/L 41.3 - 112.6 IU/L 
*p = 0.001 between subgroup 1 and control group 
** p <0.0001 between subgroup 1 and subgroup 2 
+ p = 0.0128 between subgroup 1 and control group, compared by the Mann-Whitney test. 
H. pylori-specific IgA 
No. of patients > 10 IU/L 13 (39.4%) 0 28 (84.8%) 
Median *p, +p 11.9 IU/L 2.4 IU/L 16.5 IU/L 
IQ range 3.8 - 22.7 IU/L 0 - 4.0 IU/L 8.0 - 22.5 IU/L 
* p = 0.0035 between subgroup 1 and subgroup 2 
+ p <0.0001 between subgroup 1 and control group, compared by the Mann-Whitney test 
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Table 3.2. Western blot analysis of IgG profile against H. pylori in CU and control 
group. 
H. pylori antigens Subgroup 1 Control group 
(CU with H. pylori (H. pylori-associated gastritis 
infection) without CU) 
(n = 33) (n = 33) 
120 kD 28# (84.8%) 33# (100%) 
87 kD 24 (72.7%) 28 (84.8%) 
67 kD 26 (78.8%) 27 (81.8%) 
62 kD 12(36.4%) 21 (63.6%) 
58 kD 33 (100%) 33 (100%) 
54 kD 27 (81.8%) 22 (66.7%) 
47 kD 15 (45.5%) 19(57.6%) 
44 kD 19(57.6%) 18 (54.5%) 
33 kD 20 (60.6%) 12 36.4%) 
29 kD 23 (69.7%) 20 (60.6%) 
28 kD 31 (93.9%) 32 (96.9%) 
25 kD 26 (78.8%) 22 (66.7%) 
19 kD 31 (93.9%)* 7(21.2%) 
# number of positive patients. 
* p < 0.0001 compared to control group, Fisher's exact test 
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Table 3.3. Western blot analysis of IgA profile against H. pylori in CU and in the 
control group 
H. pylori antigens Subgroup 1 Control group 
(CU with H. pylori (H. pylori-associated gastritis 
infection) without CU) 
(n= 13) (n = 16) 
120 kD 9# (69.2%) 12# (75%) 
87 kD 8 (61.5%) 10(62.5%) 
67 kD 5 (38.5%) 8 (50.0%) 
62 kD 12(92.5%) 15 (93.8%) 
58 kD 11 (84.6%) 15 (93.8%) 
54 kD 6 (46.2%) 6 (37.5%) 
47 kD 3 (23.1%) 4 (25.0%) 
44 kD 4 (30.7%) 4 (25.0%) 
33 kD 1 (7.7%) 2 (12.5%) 
29 kD 5 (38.5%) 5(31.3%) 
28 kD 9 (69.2%) 7 (53.8%) 
25 kD 2(15.4%) 3 (18.7%) 
19 kD 6(46.1%)* 1 (6.3%) 
# number of positive patients. 
* p < 0.0029 compared to control group, Fisher's exact test 
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Fig. 1. IgG Western blot results. PI and P2 are CU patients infected with H.pylori and 
C is a patient from the control group. 
PI P2 MW(kD) C 
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